 LAVA Therapeutics NV NASDAQ: LVTX announced initial data from its first clinical study with LAVA-051. The presentation will include data from the first three cohorts of the LAVA-051 Phase 12a trial, along with preclinical data on its two lead programs, LAVA-051 and LAVA-. 